LARSTARMA
Dead / Abandoned — Abandoned — no statement of use filed (as of 16 Feb 2026)
What this means for you
This application is over — abandoned 16 Feb 2026. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97477214
- Mark type
- Stylized text
- Filed
- 27 Jun 2022
- Published for opposition
- 16 May 2023
- Abandoned
- 16 Feb 2026
- Attorney of record
- Lori Wolfe
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the treatment of auto-immune diseases; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations, namely, oral and injectable contraceptives, women's hormone replacement medications
Owner
- Teva Pharmaceuticals USA, Parsippany, NJ, US
- Teva Pharmaceuticals USA, Parsippany, NJ, US
Prosecution history
- 18 Mar 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 18 Mar 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 18 Mar 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 16 Feb 2026 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 16 Feb 2026 — ABANDONMENT - NO USE STATEMENT FILED
- 27 Jun 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 Jun 2025 — SOU EXTENSION 4 GRANTED
- 26 Jun 2025 — SOU EXTENSION 4 FILED
- 26 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 18 Dec 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 18 Dec 2024 — SOU EXTENSION 3 GRANTED
- 18 Dec 2024 — SOU EXTENSION 3 FILED
- 18 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 09 Jul 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Jul 2024 — SOU EXTENSION 2 GRANTED